^
Association details:
| Biomarker: | SETD2 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4153 / 15 - SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma
Published date:
03/15/2023
Excerpt:
SETD2 mutations were associated with a higher response rate and prolonged overall survival in ICB-treated RCC patients, but not in non-ICB-treated RCC patients….This study reveals that SETD2/Setd2 loss and ATR inhibitor synergize to enhance cGAS signaling and RCC tumor immune responsiveness, and provides mechanism-based guidance to develop more personalized combination therapy regimens for RCC patients with SETD2 mutations.
Source:
Title:
Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes.
Published date:
02/13/2023
Excerpt:
2-yr OS for pts with a VHL mutation was 93% (95% CI: 82-97) vs. 68% (95%CI: 54-78) for pts without (p=0.01)... For pts with SETD2 mutations treated with IO/IO, mPFS was 0.7yrs (95%CI 0.3-1.2) vs. 1.4yrs (95%CI 0.8-1.9) for IO/TKI (p=0.01). For pts with BAP1 mutations treated with IO/IO, mPFS was 0.4yrs (95%CI 0.2-1.2) vs. NE (95%CI 0.2-NE) for IO/TKI (p=0.04)...VHL mutation was associated with improved 2-yr OS. Pts with SETD2 and BAP1 mutations treated with IO/TKI had improved mPFS...
DOI:
10.1200/JCO.2023.41.6_suppl.700
